Abstract: Phosphodiesterases (PDE) are a class of proteins whose most relevant biological activity concerns the modulation of intracellular levels of cyclic nucleotides, e.g., cGMP and cAMP. PDE isoenzyme 5 (PDE5) is specifically involved in cGMP inactivation in the smooth muscle cell. Chemical inhibition of PDE5 by sildenafil, tadalafil or vardenafil recently became a valid therapeutic option aimed at overexpressing the molecular pathway originated from nitric oxide and expressed via increased cell cGMP availability. Based on the optimal tolerability and proven efficacy in various human disorders, EMEA and FDA have approved PDE5 inhibition as an efficient therapy in some cardiovascular, pulmonary and vascular diseases. More specifically, PDE5 inhibition appears successful for the treatment of idiopathic arterial pulmonary hypertension. Furthermore, PDE5 inhibition resulted in important protective effects in the myocardium, i.e., antyhypertrophic and antiapoptic, as well as vascular functions, i.e., increased tolerance to ischemia/reperfusion injury and improved endothelial function, thereby implying a potential usefulness in the treatment of patients with heart failure and coronary artery disease. Evidence currently available for considering PDE5-inhibition an additional opportunity in the treatment of common cardiopulmonary disorders is here provided.
INTRODUCTION
In this review we will attempt to indicate the principal features of the PDE5-inhibitors, the basic underlying mechanisms and their potential therapeutic implications. Because more extensive experience has been gained with sildenafil, the main inferences and perspectives will be drawn from results obtained with this substance.
Sildenafil is a specific inhibitor of phosphodiesterase enzyme type 5 (PDE5). Commercialized under the trade name Viagra, today it is widespread known as a primary oral therapy for male erectile dysfunction, thanks to a potent relaxant effect on corpus cavernosum smooth muscles by prolonging cyclic guanosine monophosphate (cGMP) actions. However, contrarily to the general belief, sildenafil was not originally developed for the treatment of erectile dysfunction, but was the result of a program coordinated by Pfizer aimed at developing a selective inhibitor of PDE5 to augment the molecular pathway originated from nitric oxide (NO) and pursued via cyclic GMP (cGMP) signaling for the treatment of angina pectoris. Although early phase I trials performed in 1991 and 1992 showed that sildenafil had simple linear kinetics and only slightly lowered blood pressure (6-8 mmHg, compared with placebo) in healthy volunteers [1] , its relative short half-life (4 h) and modest hemodynamic properties were not viewed as significant improvement over commonly used nitrate drugs. However, later it was discovered that modulating the NO/cGMP path by inhibiting the PDE5 reaction was indeed a good therapy for some cardiovascular diseases.
In the next subheadings we, therefore, provide a revision on the basic mechanisms and the clinical evidence for PDE-5 inhibition in cardiovascular disorders.
BASIC MECHANISMS

Cyclic Nucleotides Signaling
The scheme for the cyclic nucleotides signaling is illustrated in Fig. (1) . Cyclic nucleotides, e.g., adenosine cyclic 3',5'-monophosphate (cAMP) and guanosine cyclic 3',5'-monophosphate (cGMP), *Address correspondence to this author at the Cardiopulmonary Unit, University of Milan, San Paolo Hospital, Via A. di Rudinì 8, 20142 Milan, Italy; Tel: +39-02-50323144; Fax: +39-02-50323144; E-mail Marco. Guazzi@unimi.it are important second messengers that regulate a variety of functions in many cell types. They are involved in the control of an increasing number of physiological processes and have multiple intracellular targets including gated channels and protein kinases.
Cyclic nucleotides are synthesized from their respective nucleotide triphosphates, e.g., adenosine triphosphate (ATP) and guanosine triphosphate (GTP), in reactions catalyzed by adenylyl cyclase and guanylyl cyclase, respectively. Whereas adenylyl cyclase is a membrane protein coupled to the -adrenergic receptor system, guanylyl cyclase is a cytoplasmic protein, hence its name of soluble guanylyl cyclase (sGC), which is under the control of membrane-permeable messengers. The main target of cAMP is the activation of protein kinase A, while cGMP acts through protein kinase G, which is responsible for the reduction of intracellular Ca ++ levels and the activation of mitochondrial respiration. The physiological effects of cGMP and cAMP are attained when their level is 2-3 times the basal unstimulated one [2] , thus, for both nucleotides, a continuous rapid synthesis and rapid degradation enable cells to respond quickly to a number of stimuli.
The process that is of greatest interest in this review concerns the cGMP-mediated vasorelaxation. In the smooth muscle, cGMP initiates a cascade of reactions that decrease intracellular Ca ++ and promote relaxation [3] . Of interest, the cGMP-dependent vasorelaxation is not only dependent on the normal function of the peripheral autonomic nervous system, but also on the functional integrity of the vascular endothelium [4] . Therefore, there must be an important role of the NO/cGMP pathway in the control of smooth muscle tone and the regulation of intracellular Ca ++ release in the smooth muscle cell requires strict synergism between NO and cGMP [5] .
Modulation of CGMP by NO and Nitrates
Although most extracellular signals are hydrophilic molecules that bind to a receptor on the surface of the target cells, some signal molecules are hydrophobic or small enough to pass readily across the target-cell plasma membrane and regulate the activity of an intracellular protein. NO is a remarkable example of the latter class. The vasorelaxation effect of NO provides an explanation for the action of nitroglycerine that is being used since over a century to treat angina pectoris, which stems from inadequate blood flow to the cardiac muscle. The only cell reaction that originates NO is Arginine + NADPH + O 2 Citrulline + NADP + + NO, catalyzed by NO synthases. The half-life of NO in the circulation is 5-10 s, after which NO is converted to nitrites and nitrates. Recent evi-dence suggests that red cell hemoglobin is able to convey NO to hypoxic tissues by at least two mechanisms. In the first, deoxygenated hemoglobin acts as an enzyme to facilitate conversion of plasma nitrites into NO [6] . In the second, NO release from red cell S-nitrosohemoglobin becomes faster at low PO 2 [7] . Both mechanisms enhance NO-dependent vasorelaxation, especially when blood supply to tissue is limited. Another fraction of NO is produced in the endothelial cells in response to stimulation of the acetylcholine receptor. Whatever the source, when inside the smooth muscle cell, NO binds to the iron core of sGC enabling faster conversion of GTP into cGMP [8] . Louis J. Ignarro, Robert F. Furchgott and Ferid Murad won the Noble Prize in Physiology and Medicine in 1998 "for their discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system".
Nitrates, an exogenous source of NO still in widespread clinical use for the treatment of CV diseases, especially angina pectoris, are drugs that act as vasodilators of both arteries and veins [9] . However, their therapeutic potential is limited by the rapid induction of tachyphylaxis, e.g., reduced responsiveness to a drug, which requires dose up-regulation to maintain the same level of efficacy [10] . Historically, this phenomenon was known since the beginning of the century, when the nitroglycerine industry flourished, exposing workers to high levels of organic nitrites. The phenomena of nitrate tolerance was recognized by the onset of 'Monday disease' and of nitrate-withdrawal or overcompensation by 'Sunday Heart Attacks' [9] . In addition, the impracticability of long-term NO or nitrate therapy, forced investigations into other mechanisms that allow persisting NO-originated signaling path without using nitrates.
Phosphodiesterases
Earl W. Sutherland, winner of Nobel Prize for Physiology and Medicine in 1971 "for his discoveries concerning the mechanisms of the action of hormones", first determined the role of phosphodiesterases (PDE) in maintaining the intracellular levels of cAMP and cGMP [11] . By cleaving the 3',5'-cyclic phosphate moiety, these Mg ++ -dependent phosphohydrolases hydrolyze the phosphodiester bond of cAMP and cGMP to form the inactive linear 5'-AMP or 5'-GMP, thereby abolishing their biological activity. The regulation of the enzymes that control the breakdown of cGMP, as opposed to its synthesis, has proven to be pivotal in maintaining appropriate levels of cAMP or cGMP in the cell [12] .
Eleven families of PDEs with varying selectivity for cAMP or cGMP have been identified in mammalian tissues ( Table 1) . Within these families, more than 40 isoforms are expressed either as products of different genes or as products of the same gene through alternative splicing [2] . In vertebrates, hydrolysis of cGMP is specifically performed by only some of the PDEs [13] , whereas other PDEs are dual-specificity enzymes that hydrolyze both cAMP and cGMP. The various PDEs display noticeable (>65%) aminoacid homology and the high conservation in the catalytic domain suggests that PDEs pre-date the evolutionary divergence of eumetazoans from fresh-water sponges [14] . Studies in Drosophila showed a high degree of similarity in structure and function between human and Drosophila PDEs [15] , thereby allowing future transgenesis and mutagenesis investigations to discover fundamental physiological processes governed by PDEs.
Among all PDEs, PDE5, the cellular target of sildenafil as well as other PDE inhibitors (PDEI), has been extensively characterized [2] . The human PDE5 gene is located on chromosome 4q26 and comprises 23 exons encompassing more than 100 kb. A PDE5A promoter preceding these exons includes a 139-bp core, as well as a 156-bp downstream enhancer and a 308-bp upstream enhancer. The PDE5A promoter is inducible by cGMP [16] . The PDE5 protein is a homodimeric, cytosolic enzyme consisting of two identical 99-kDa subunits. Each subunit is a chimeric protein comprising both a carboxy-terminal metal-binding catalytic domain and an aminoterminal regulatory (allosteric) domain [14] . Within the regulatory domain, there are two identical tandem homologous sequences of 110 amino acids (GAF a and b domains). PDE5 is a zinc-dependent enzyme with high substrate specificity for cGMP (Km=1-5 μM) over cAMP (Km=300 μM). The regulatory domain in the aminoterminal portion of PDE5 contains a phosphorylation site (Ser 92 ), two allosteric cGMP-binding sites, a and b, and at least a portion of the dimerization domain. The catalytic domain in the carboxyterminal portion of the protein contains the two Zn ++ -binding motifs A and B, and a cGMP substrate-binding site [17] . The three PDE5A isoforms differ only in the 5' end of the mRNAs [18] .
Chemistry of PDE Inhibitors
The chemical formulas of the inhibitors of PDE considered in this review are shown in Fig. (2) . The citrate form of sildenafil, initially named UK-92,480, is now better known with its trade name Viagra, which entered clinical trials in 1991 as specific inhibitor of PDE5 [19] . NMR-based methods have been developed for the identification and quantization of sildenafil in its various pharmacological formulations [20] . Today, two other specific PDE5I have been marketed: vardenafil (Levitra) and tadalafil (Cialis) [21] . The core ring of PDEI mimics the structure of the purine base in cGMP and interacts exclusively with the same PDE5 catalytic site without any effect on its regulatory domain. Binding of either a PDE5I or cGMP to one catalytic domain does not appear to kinetically influence the activity of the catalytic domain on the other monomer.
Three PDE5 isoforms, called PDEA1, PDEA2 and PDEA3, were described [22] . While PDE5A1 and A2 isoforms are widespread expressed in several tissues, the A3 isoform is confined to tissues with a smooth muscle or cardiac muscle component. PDE5A1, A2, and A3 isoforms have similar cGMP-catalytic activities with Km of 6.2, 5.75, and 6.06 μM, respectively.
To allow insight into the interaction between PDE5 and PDEI, the three dimensional structure of the enzyme catalytic site (residues 537-860) has been modeled using X-ray crystallography [23] . The PDE5 catalytic site comprises three helical subdomains: a Cterminal helical bundle (residues 726-860), a linker region (residues 679-725), and a N-terminal cyclin-fold domain (residues 537-678). The PDE5Is bind to the catalytic site with a stoichiometry of 1 mole of PDE5I per PDE5 subunit. The PDE5 active site is accessed via a narrow (1 nm) cleft housed within a larger 33 nm substrate pocket containing four subdomains. These include a metalbinding region (M site), a core pocket (Q pocket) and two other regions less intimately involved in PDE5 binding by sildenafil and vardenafil: a hydrophobic pocket (H pocket) and a lid (L region). Possibly because PDE5Is are large molecules with more extensive interactions with Q-pocket amino acids, they bind 1000 times more avidly to the catalytic site than cGMP does.
The three PDEI have similar but not identical mechanisms of action. Despite close structural similarity, vardenafil is 32-fold more potent than sildenafil to inhibit PDE5; this is due to differences between their heterocyclic rings that affects reactivity with Tyr 612 [24] . Gln 817 in PDE5 is a positive determinant for PDE5 affinity for cGMP and several inhibitors, whereas Gln 775 , which perhaps restricts rotation of Gln 817 side chain, is critical for cGMP affinity but it has no measurable effect on affinity for cAMP, sildenafil, or vardenafil [25] . Mutagenesis and kinetic analyses confirm that the H-loop is particularly important for substrate recognition and that invariant Gly 659 , which immediately precedes the H-loop, is critical for optimal substrate affinity and catalytic activity [26] . The N-terminal 46 amino acids in the GAF-B domain are required for high vardenafil potency over sildenafil and tadalafil and is involved in PDE5 dimerization [27] . Furthermore, in the rat aorta, vardenafil, but not sildenafil or tadalafil, affects Ca ++ handling in addition to increasing cGMP levels through inhibition of PDE5 to cause relaxation [28] .
The selectivity of the three PDEI upon other PDE families varies. For example, although very selective for PDE5, sildenafil displays some cross-reactivity with PDE6, which is the predominant form in photoreceptors [29] , thereby explaining transient disturbances in color vision perception in people taking high doses of sildenafil, which has low selectivity over PDE6 [30] . Another known cross-reactivity is that with PDE11, the most recently discovered member of the PDEs superfamily, which appears to be the one more susceptible for cross-reaction by PDEI's, and it was questioned if one of the side reactions of tadalafil administration (back pain and myalgia) could be attributed to low selectivity of tadalafil for PDE5 over PDE11. PDE11 occurs in four variants in humans and is currently under investigation for the treatment of several diseases including asthma, acute ischemic stroke, cancer, systemic inflammation pulmonary hypertension and others [2, 31] , however none of the three PDEI's is likely to crossreact with PDE11A4 in patients [31] .
Pharmacokinetics
Sildenafil has a rapid onset of action and a plasma half-life of 4 h [32] [33] [34] . The duration of action was originally estimated at 4-6 h based on its plasma half-life, but empirical testing shows that sildenafil can have effects for up to 12 h [35] . Hepatic metabolism, via the cytochrome P450 (CYP450) enzymes CYP3A4 (major route) and CYP2C9 (minor route), is the principal route of metabolism and elimination of sildenafil [35] . Thus, any drug that induces or inhibits the expression or activity level of CYP450 enzymes has the potential to alter peak plasma levels and the systemic exposure (AUC) of sildenafil. Protease inhibitors, included in highly active antiretroviral therapy (HAART; indinavir, nelfinavir, saquinavir and ritonavir) and the macrolide antibiotic erythromycin, are CYP3A4 inhibitors. Coadministration of sildenafil did not significantly alter HAART plasma levels. However, plasma sildenafil AUC was markedly increased by these protease inhibitors and by erythromycin, but not by azithromycin (reviewed in [1] ). However, the results of numerous studies are consistent; most commonly used medications do not significantly interfere with the pharmacokinetics of sildenafil. Thus, sildenafil can be administered with a very wide range of other medications, is well tolerated and does not alter the biochemical and physiological effects of most drugs.
PDE-Inhibition in the Heart
Myocardium
Because PDE5A is expressed at low levels in the myocardial cell, sildenafil is unlikely to directly produce inotropic effects on cardiac muscle [36] . PDEI induce only a slight decline in arterial pressure and have no apparent effect on cardiac ejection fraction or output at rest, as reviewed in greater detail below. Oral sildenafil produced only small decreases (<10%) in systemic arterial and pulmonary arterial pressures, and had no effect on pulmonarycapillary wedge pressure, right atrial pressure, heart rate, or cardiac output. There were no significant changes in average peak coronary flow velocity, coronary-artery diameter, volumetric coronary blood flow, or coronary vascular resistance. Coronary flow reserve at base line was lower in the stenosed arteries than in the reference arteries and increased about 13% in both groups of arteries combined after the administration of sildenafil. The ratio of coronary flow reserve in coronary arteries with stenosis to that in the reference arteries was not affected by sildenafil [37] . However, despite low expression levels, PDE5A can exert potent localized regulation over adrenergic stimulation. For example, PDE5A inhibition by sildenafil blunts systolic responses to -adrenergic stimulation [38] . The regulatory role of PDE5A in hearts under adrenergic stimulation is specifically coupled with eNOS-dependent mechanisms [39] .
Sildenafil suppresses chamber and myocyte hypertrophy and improves in vivo heart function in mice exposed to chronic pressure overload induced by transverse aortic constriction. PDE5A inhibition deactivates multiple hypertrophy signaling pathways triggered by pressure load (the calcineurin/NFAT, phosphoinositide-3 kinase (PI3K)/Akt, and ERK1/2 signaling pathways), but does not suppress hypertrophy induced by overexpression of calcineurin in vitro or Akt in vivo, suggesting upstream targeting of these pathways [40] . Increased cGMP level by sildenafil is cardioprotective probably through acting as a post-receptor negative regulator of cardiac sympathetic responsiveness, with integrity of NOS function essential prerequisite for sildenafil's action [41] .
Cardioprotection, Ischemic Preconditioning
Since 1986, it was acknowledged that repeated brief exposures to sublethal ischemia do not have cumulative effects in terms of metabolic derangement [42] . Later, it was appreciated that such operation may confer myocardium some degree of protection against ischemia/reperfusion [43] [44] [45] [46] [47] , which has been named ischemic preconditioning (IP). IP is associated with two forms of protection: a classical form lasting approximately 2 h after the preconditioning ischemia followed a day later by a second window of protection (SWOP) lasting approximately 3 days [48] . Both types of preconditioning share similarities in that the preconditioning ischemia provokes the release of several autacoids that trigger protection by occupying cell surface receptors. From time to time, a range of different pharmacological agents have been identified that activate the signaling cascades at the various levels and mimic IP, thereby leading to the hope that specific therapeutic agents can be designed to exploit the profound protection seen with IP. Sildenafil revealed a powerful IP-like effect in hearts from rabbits [49] , mice [50] and rats [51] .
There appears to be more than one mechanism underlying sildenafil-induced cardioprotection, most likely synergistic. One category of mechanisms involves opening of mitochondrial ATPdependent K + channels (K + ATP, mito ) [49] . Perhaps, a pivotal role is played by early translocation of protein kinase C to the membranous fraction [52] , which opens of K + ATP, mito [53] and prevents cardiomyocytes necrosis and apoptosis [54] . The role of K + ATP, mito opening was confirmed in human studies [55] .
It became evident that K + ATP, mito opening is not the only mechanism, because sildenafil-induced protection against necrosis and apoptosis was attenuated in iNOS-knockout mice and eNOSknockout myocytes, thereby envisaging a critical role for NO signaling [54] . The link between sildenafil and NO derived from iNOS seems suggestive because NO has been identified as an essential mediator of SWOP [56] . In support of this view, it has been reported that sildenafil caused a significant increase in iNOS mRNA (+45%, 2 h after sildenafil injection) and, to a lesser extent (+15%, 1 h after sildenafil injection) of eNOS mRNA [50] . Such increases in mRNA ultimately reflect into more persistent (24 h) increases in the respective proteins [50] . The two paths are however linked one to the other because increased NO may act on K + ATP, mito opening, cGMP intracellular levels and Bcl-2, to blunt the effects of ischemia/reperfusion on Ca ++ -mediated cell swelling and mitochondriamediated apoptosis (Fig. 3) .
In a clinical perspective, sildenafil does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina [57] , and multiple papers suggest a potential utility of sildenafil in Fig. (3) . Scheme for the interaction among ischemia-reperfusion, PDE-5 inhibition and myocardial necrosis and apoptosis. ICa, inward calcium current; K ATP, ATP-dependent potassium channels; ROS, reactive oxygen species.
protecting ischemic myocardium and treating stroke. Sildenafil dilates epicardial coronary arteries, improves endothelial dysfunction and inhibits platelet activation in patients with coronary artery diseases [58] . Sildenafil was tolerated and effective for erectile dysfunction treatment in chronic heart failure, and improved the exercise capacity. The reduction of heart rate during exercise with sildenafil could theoretically decrease the myocardial oxygen consumption during sexual activity [59] . Peripheral vasodilatory effects of sildenafil, possibly related to NO may be accompanied by a decrease of systemic blood pressure and reduced arterial wave reflection [60] . Acute PDE5 inhibition with sildenafil 25 and 50 mg increases endothelium-dependent, flow-mediated vasodilatation in patients with chronic heart failure [61] . Sildenafil treatment has a favorable effect on brachial artery flow-mediated dilatation that persists for at least 24 h after the last dose [62] .
Lungs
As far as the pulmonary system is concerned, in class 1, or idiopathic pulmonary arterial hypertension, PDE5 gene expression is upregulated [63] and several non-specific inhibitors of PDE ameliorate PAH as reviewed in [19] . Sildenafil reduced pulmonary vascular resistance in patients with various forms of pulmonary hypertension [19] . Sildenafil protects against the development of altitude-induced pulmonary hypertension by improving gas exchange, limiting the altitude-induced hypoxemia and decrease in exercise performance [64, 65] . The inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension [66] . Sildenafil exerts an antiproliferative effect on human pulmonary artery smooth muscle cells that is mediated by an interaction between the cGMP-Protein kinase G and the cAMP-Protein kinase A activated pathways, leading to inhibition of PDGF-mediated activation of the ERK pathway [67] .
PDE-5 Inhibitors in Hypoxia
Chronic hypoxia, an important component of the pathology associated to cardiovascular disorders, requires a toll of 750,000 patients per year in the US. Hypoxia is a potentially lethal situation originating from low O 2 supply with respect to needs. The various organs in the body respond differently to hypoxia depending on their O 2 demand, supply and utilization [68] . In the myocardium, which is strictly dependent on O 2 for its metabolism and has low regeneration capacity, severe hypoxia increases substantially the expression of hypoxia-induced transcription factors and the associated expression of MAP kinases, especially p38 MAP kinase [69] . Furthermore, chronic exposure to hypoxia greatly increases the extent of apoptosis [68] . In brain tissue, both these responses are reverted by non-erythropoietic erythropoietin derivatives, which implies that improving the blood-O 2 carrying properties is ineffective with respect to anti-hypoxic protection [70] . PDE-5 inhibitors are known to have important protective effects in organisms subjected to hypoxia challenges. For example, in primary or hypoxiainduced pulmonary hypertension [71] and myocardium infarct following ischemia/reperfusion [50] . As for the underlying molecular mechanisms, it appears that sildenafil prevents hypoxia-induced apoptosis in myocardial cells, most probably via p38-ERK1/2 and NO signaling pathways [50, 54, 72] .
Clinically, PDE-5 inhibitors are being investigated in the treatment and prevention of high altitude pulmonary edema [73] , pulmonary hypertension [65] and in general during adaptation to hypoxic conditions [74] . Sildenafil has been shown to improve cardiac output and exercise performance during acute hypoxia, although not during normoxia, because during cycling exercise in acute hypoxia, sildenafil greatly improved cardiovascular function, S a O, and performance for certain individuals [75] . Thus, although the mechanisms underlying the favorable effects of sildenafil and other PDE-5 inhibitors are not yet being fully resolved, there are clear indications that this therapy may become a major target in treatment of this lethal situation.
CLINICAL DEVELOPMENTS
There is no question that clinicians have to face with the growing and convincing documentation that PDE-5 inhibitors may have many therapeutic potentials separate from their major original clinical use, which is the treatment of erectile dysfunction in men. This class of drugs has been shown to exert important vascular and myocardial protective effects, implying a potential usefulness in treating patients with coronary artery disease (CAD), heart failure (HF) and pulmonary arterial hypertension (PAH).
PDE5-Inhibition in CAD
Most of the risk factors for patients with CAD are the same for erectile dysfunction. Because of this, following the approval of PDE5 inhibition for the cure of erectile dysfunction, potential harmful effects on the heart of this class of drugs have been considered carefully. Initial isolated reports raised the concern that PDE5 inhibition (eventually associated with nitrates) may increase the risk of cardiovascular events in patients with CAD by induction of unfavorable influences on coronary and systemic hemodynamics [76, 77] .
Nowadays, a significant amount of evidence based on controlled and open-label studies indicates that use of PDE-5 inhibitors generally has a safety profile in this category of patients [78] [79] [80] [81] [82] [83] [84] .
PDE5-Inhibition on Systemic Hemodynamics and Peripheral Vasculature
In normal volunteers, administration of 80 mg of sildenafil caused an average systolic and diastolic blood pressure fall of 9 mmHg and 7 mmHg, respectively, without changes in heart rate. In the same study [85] , the effects of 100 mg, 150 mg and 200 mg in a single dose were assessed. The mean maximum reduction in supine systolic and diastolic blood pressure was 10 and 7 mmHg after 3 h, with no differences between the 200 mg and the 100 mg dose. No significant drop in the passage from supine to orthostatic position was observed and in most subjects blood pressure reversed to normal within 6 h [85] . Similar systolic and diastolic blood pressure drops were obtained with vardenafil 20 mg, with maximum changes occurring between 1 and 4 h 1 .
Tadalafil, whose chemical structure substantially differs from that of sildenafil and vardenafil and which has a long half-life of 17.5 h, induces smaller changes in systemic blood pressure. A single oral dose of 10 or 20 mg administered to healthy volunteers did not lower significantly standing systolic blood pressure compared to placebo (-0.2 mmHg), while the mean decrease in diastolic blood pressure was -4.6 mmHg and persisted for 12 h. Changes were even less marked in the supine position and heart rate did not vary in both standing and supine position [86] .
In studies performed in patients with CAD, intravenous sildenafil (40 mg) and oral tadalafil (10 mg) caused small reductions in systolic and diastolic blood pressure without changes in heart rate as well [37, 87, 88] . Thus, PDE5 inhibitors are mild vasodilators that cause minimal decrease of blood pressure and no changes in heart rate in normal individuals as well as in CAD patients.
Overall, drug safety is based on the observations that PDE-5 inhibition is not associated with ischemic events either when taken acutely or during chronic use and that drug discontinuation because of adverse effects is similar to placebo. However, concern rises in patients taking nitrates [89, 90] orblockers. The arterial vasodilating property also becomes an issue in patients with left ventricular outflow obstruction [91] .
PDE5-inhibition and Nitrates Interaction
PDE-5 inhibition with sildenafil does not negatively interact with most antihypertensive or antianginal therapies [86] ; there is, however, confirmatory evidence that all three PDE5 inhibitors on the market in conjunction with nitrates are proscribed [88] [89] [90] . This is because short and long acting organic nitrates stimulate guanylyl cyclase, which increases cGMP production. When a PDE5 inhibitor is prescribed in association with nitrate there is a combinatory increase in cGMP concentration, due to overproduction and inhibited breakdown, which may turn into severe hypotension. Guidelines recommend a 24-h time interval between the administration of any NO donor and sildenafil, or viceversa [91] .
Endothelial Dysfunction
The endothelium plays a major contributory role in the development of arteriosclerosis and acute coronary syndromes [92] . In vivo measures of endothelial function have established their prognostic value for cardiovascular events [93, 94] 2 . Furthermore, there is evidence that a phenomenon similar to myocardial preconditioning following ischemia-reperfusion (IR) injury may be elicited in vivo at the level of forearm artery [95] . Gori et al. [55] have recently tested in 10 normal volunteers the potential protective effect of sildenafil (50 mg) vs placebo on endothelium-dependent brachial artery flow-mediated dilation (FMD) impairment induced by IR (15 min of ischemia followed by 15 min of reperfusion). Sildenafil, as compared to placebo, significantly limited the IR-induced FMD impairment. Since the protective effect was abolished by sulfonylurea glibenclamide, a blocker of K + ATP channels, a specific activity on these channels may be inferred as putative mechanism. Implications and perspectives of these findings need to be tested further.
Independently of a modulatory effect on IR, sildenafil may directly affect endothelial dysfunction in some risk conditions associated with CAD, such as smoking habit [96] and diabetes [62] . However, neutral effects have been reported in hypertensive patients [97] and results obtained in CAD patients are conflicting [58, 98] .
PDE5-Inhibition on Coronary Circulation and Myocardial Protection
In canine coronary arterial wall segments, accumulation of cGMP was observed after incubation with sildenafil [99] . Accordingly, in the vascular smooth muscle of isolated canine coronary arteries, sildenafil has been demonstrated to enhance cGMP levels in a dose-dependent manner increasing concentrations by 10 to 100 nmol/L [100] . These findings indicate that cGMP breakdown at coronary level depends, at least in part, on PDE5 activity in coronary arteries. However, since PDE1 activity has been identified to largely contribute to cGMP-hydrolyzing activity from 73% to 80% [101] , it may be inferred that, at coronary circulation level, most of the cGMP breakdown persists despite PDE5-inhibition. In contrast with the initial idea that sildenafil might cause a coronary steel phenomenon, studies performed in dogs have shown a significant sildenafil-induced increase in coronary blood flow at rest and during exercise [102] [103] [104] . Measurement of coronary blood flow by an intracoronary Doppler wire before and after sildenafil in patients with CAD showed no changes in flow. Sildenafil 100 mg actually improved coronary flow reserve in both normal and stenosed arteries as measured after 45 min post intracoronary adenosine [37] .
Clinical Use of PDE5-Inhibitors in CAD
Originally, sildenafil was tested as an antianginal drug targeting PDE5 in the systemic vasculature [105] . Results obtained with all PDE5-inhibitors have shown that when these agents are administered to stable CAD patients performing an exercise stress testing, there is no ischemia exacerbation [106, 107] and there may be a beneficial effect on exercise-induced ischemia.
In a double-blind placebo-controlled crossover study of 105 men at high risk for CAD, exercise echocardiography was used to compare the effects of 50 mg and 100 mg doses with placebo [106] . No adverse effects on left ventricular wall motion score were observed with a similar hemodynamic response regarding heart rate, blood pressure, double product, and exercise capacity.
In a multireport study by Fox et al. [57] performed in 108 men with stable angina, 100 mg of sildenafil was tested. The primary end point was time to limiting angina, and secondary end points included time to angina, time to ST-segment depression, and exercise duration. All patients had reproducible ischemia at baseline and underwent exertion on a treadmill 1 h after sildenafil or placebo. Sildenafil significantly increased primary and secondary end-points (p<0.05) but time to ST depression; however, the trend was favorable. Sildenafil was not associated with increase in adverse events and was generally beneficial in this stable population.
Halcox et al. [58] compared sildenafil 100 mg with isosorbide dinitrate 10 mg versus placebo in 24 patients with stable CAD in a double-blind randomized study. No differences were observed in exercise time or rate-pressure product for all 3 treatments, but ST depression was less while on nitrate at peak exercise (p<0.05). Once more, sildenafil showed a favorable therapeutic trend that failed to reach significance, probably because of the small number of investigated subjects.
Vardenafil (10 mg), in comparison to placebo, did not adversely alter treadmill exercise time or time to angina but it did significantly prolong time to ischemic threshold (p=0.0004) in 41 stable patients with CAD and reproducible angina [107] .
Interestingly, an improvement in coronary artery vasodilator reserve induced by adenosine was observed after oral sildenafil administered to patients with severe CAD [37] .
PDE5-Inhibition in PAH
PAH is a severe, often fatal disease, characterized by welldefined clinical hallmarks such as important breathlessness, exercise intolerance and progressive advance to right ventricular failure and death. The disease has various origins, whose classification has recently been revised at the Third World Conference on Pulmonary Hypertension held in Venice in 2004 [108] . Accordingly, five subclasses of PAH can be recognized. A note of mention is needed for Class I, which includes the so-called PAH group consisting of diseases that share similar pathophysiology, pathology and prognostic features. In this context, the more prominent and representative form of this class is idiopathic PAH (iPAH), which was formerly identified as primary pulmonary hypertension, and which is characterized by loss-of-function mutations in the bone morphogenetic protein type 2 receptor (BMPR2) as the most common underlying mechanism [109, 110] .
Controlled studies planned for testing PDE5-inhibition in PAH have been primarily focused on iPAH, and sildenafil is the PDE5-inhibitor most extensively tested [111] [112] [113] [114] [115] [116] .
PDE5 Expression and Pulmonary Vasodilatory Activity of PDE5 Inhibition
Given the high expression of PDE5 in lung tissue and the critical dependence of pulmonary vasomotility on NO production, PDE5 inhibition appears to be an ideal target for the pharmacological treatment of pulmonary vascular diseases. Specifically, PDE5 gene expression upregulation has been shown to occur in pulmonary hypertensive lungs [63] .
The first demonstration of a vasodilating activity on lung vessels by PDE5-inhibition was provided by Hynes et al. [117] , who studied the PDE5-inhibitor zaprinast in the isolated lung preparation exposed to hypoxia. Later on, a powerful inhibition of hypoxic pulmonary vasoconstriction was shown by Zhao et al. [118] using sildenafil, and the same authors reported that oral treatment with sildenafil of chronically hypoxic mice prevented the development of pulmonary hypertension [119] . These studies provided new insights in the cellular pathways involved in the favorable effects of sildenafil on lung vascular remodeling, showing a contribution of natriuretic peptides to increase of cGMP levels via receptor-linked activation of the particulate guanylate cyclase. In natriuretic peptide receptor A (NPR-A) knockout mice, sildenafil activity on lung vasculature was reduced [118] . In a rat model of PAH induced by monocrotaline, chronic sildenafil treatment reduced pulmonary hypertension and the expression of matrix metalloproteinase 2 and 9 with evident effect on vascular muscularization [120] . In human pulmonary artery smooth muscle cells isolated from hypertensive tissue, sildenafil showed a significant antiproliferative activity [121] .
Clinical Trials for Treatment of Pulmonary Hypertension
During the last decade we have witnessed substantial improvements in the therapeutic options for PAH with interventions more focused on targeting some of the basic mechanisms involved in the pathogenesis of the disease. Among others, PDE5-inhibition with sildenafil has gained a progressive role, and in 2005, following demonstration of very favorable mid-and long-term effects of this novel oral treatment, the FDA and the EMEA approved its clinical use in PAH.
Acute Therapeutic Effects on Pulmonary Hemodynamics
In several isolated acute studies PDE5-inhibition turned out to be a most effective therapeutic strategy aimed at overexpressing NO pathway which remarkably affected pulmonary hemodynamics and lung vessel tone of PAH patients when administered both alone [111] and in combination with other vasodilating agents [111] [112] [113] [114] [115] .
In PAH, lung vasoreactivity is traditionally tested by inhaled NO (iNO), which exerts a selective dilating activity on pulmonary vasculature [122] without causing systemic hypotension. A positive response to iNO as defined by >20% decrease of pulmonary arterial pressure (PAP) or pulmonary vascular resistance (PVR), predicts the response to conventional vasodilators and identifies patients with a better long-term prognosis [123] . Moreover, iNO is also used in patients with severe PAH secondary to left ventricular dysfunction as part of the assessment prior to cardiac transplantation [124] . However, iNO long term administration is limited by the short halflife, and its use as an acute vasodilator requires an expensive medical form of NO gas and is also technically challenging to administer continuously because of complicated delivery system and monitoring equipment. A single oral dose of sildenafil has been shown to be superior to iNO in the acute assessment of patients with PH, and their combination results in an additive pulmonary vasodilatory effect. Specifically, sildenafil was superior in decreasing the mean PAP and equally effective and selective in reducing PVR [115] . Furthermore, sildenafil has been shown to be more advantageous than iNO, because it causes a significant increase in cardiac index and does not raise pulmonary wedge pressure (PWP).
In a report of 5 IPAH patients, the acute hemodynamic effects of sildenafil were compared to those of inhaled iloprost: reduction in PAP was greater after inhaled iloprost. However, their combination lowered mean PAP significantly more than iloprost alone, without adverse effects, or significant changes in systemic blood pressure [113] . In another acute study performed by Ghofrani et al. [125] , a comparison was performed between iNO in combination with either intravenous epoprosterol or with oral sildenafil in patients with PH due to pulmonary fibrosis. There was a marked reduction of PAP with both treatments; however, a decreased ratio of pulmonary-to-systemic vascular resistance was only observed in patients receiving iNO plus sildenafil. In a large study performed by the same authors in patients with iPAH the acute effect of sildenafil on PAP and PVR was dose-dependent. Again the observed results were significantly stronger than those seen with iNO [114] .
Long-Term Treatment of PAH
Long-term treatment of patients with PAH performed in a number of single-centre studies [126] [127] [128] [129] and, recently, in the multicenter SUPER-1 (Sildenafil Use in Pulmonary HypERtension) study [116] , has confirmed the high efficacy and excellent tolerance of chronic sildenafil. In a limited number of cases, Mickelakis et al. [115] , investigated the effects of chronic treatment (3 months) with oral sildenafil (50 mg every 8 hours) added to standard therapy on clinical status, pulmonary hemodynamics, exercise tolerance and right ventricular (RV) mass. Symptomatic status and exercise tolerance improved, as suggested by a NYHA functional class improvement 1 in all patients and by an average significant increase in 6-min walk distance. Sildenafil reduced mean PAP, PVR without effects on systemic arterial pressure. Interestingly, PDE5-inhibition promoted a favorable reverse remodeling of RV chamber geometry and mass. Similar findings on exercise tolerance, symptoms and hemodynamics were reported in three other prospective trials after 2 weeks of treatment with low doses of sildenafil (25 mg every 8 h) [126] , 3 months with 50 mg every 8 hours [130] and 7 months with a median sildenafil dose of 87.5 mg/day [127] , respectively. In patients with worsening of severe PAH despite treatment with prostanoids, additional long-term administration of oral sildenafil improved exercise capacity and pulmonary hemodynamics [129] . Similar results have been confirmed at two years follow-up in 20 PAH patients with clinical or functional worsening despite ongoing treatment with prostanoids [131] .
In the SERAPH (Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension [116] ) study, a comparison of sildenafil (50 mg twice daily for 4 weeks, then 50 mg three times daily) vs bosentan (62.5 mg twice daily for 4 weeks, then 125 mg twice daily) over 16 weeks, showed a significant reduction from baseline in RV mass and plasma brain natriuretic peptide levels and improvement in 6-min walk distance, cardiac index and systolic left ventricular eccentricity index in patients treated with sildenafil. Bosentan improved only 6-min walk distance and cardiac index.
To date the largest multicenter randomized, placebo-controlled study investigating sildenafil in PAH patients is the SUPER-1 study [116] . This study included 278 patients with symptomatic PAH in functional classes II to III who were given either placebo or oral sildenafil (20, 40, 80 mg) three times daily for 12 weeks. Primary study end-point was improvement from baseline at 12 weeks in the 6-min walk test. Sildenafil was very well tolerated at all doses and ameliorated exercise tolerance, functional class and hemodynamics. Furthermore, patients who completed the double-blind phase entered a two-year duration extension trial with sildenafil 80 mg twice daily. Remarkably, improvement in functional class and 6-min walk achieved after the placebo-controlled phase, persisted even after a year of therapy [116] . Following these observations, FDA and EMEA approved the use of 20 mg twice daily, because of the flat (non-significant) dose-effect relationship between 20 and 80 mg regarding the primary end-point of the study, i.e. the change in 6-min walk distance over 2 weeks of treatment. In addition, analysis of sildenafil plasma levels in the SUPER-1 study showed no doseeffect relationship with various dosages [19] .
Forms of PAH other than iPAH, which have been investigated, include lung fibrosis [125] , thromboembolic PAH [132] , PAH sec-ondary to congenital heart disease and Eisenmenger syndrome [133] [134] [135] , PAH due to human immunodeficiency virus (HIV) [136] . Sildenafil seems to be effective in most of these forms. Interestingly, PDE5 inhibition with sildenafil has recently emerged also as a therapeutic strategy for high-altitude PAH. Favorable results on exercise performance and lung hemodynamics have been reported in small studies [64, 65, 119] and the efficacy is linked to the drug ability to reverse hypoxia-mediated pulmonary vasoconstriction.
PDE5-Inhibition in HF
The consistent efficacy of PDE5-inhibition in iPAH has led to the investigation of potential utility of the compound in the treatment of HF patients with secondary PAH. However, the suggested usefulness of PDE5 inhibition in HF has grown rapidly thanks to the demonstration of a variety of actions in addition to the effects on pulmonary hemodynamics. Most of the clinical experience accumulated with the use of PDE5-inhibition in HF derives from studies using sildenafil in acute settings.
Effects on Cardiac Hypertrophy and Left Ventricular Function
Studies performed in animals have provided the interesting demonstration that chronic PDE5-inhibition is effective in the control of important cellular and molecular pathways involved in the morphological and functional changes leading to maladaptive left ventricular remodeling and heart failure [40, 54] . In particular, recent experiments performed in hearts exposed to sustained pressure overload have demonstrated that sildenafil exerts a direct antihypertrophic effect in a protein kinase G1-dependent manner by deactivation of multiple cardiac hypertrophy signaling pathways (the calcineurin/FAT, phosphoinositide-3 kinase (PI3K)/Akt and ERK1/2) [40] . Consistently, in an isoproterenol-induced cardiac hypertrophy model in rats, cGMP levels were shown to be inversely correlated with cardiac hypertrophy [41] . Furthermore, Das et al. [54] demonstrated that sildenafil exerts a direct protective influence on myocytes apoptosis. An attenuating effect on myocytes apoptosis and left ventricular dysfunction was also observed in a chronic model of doxorubicin cardiotoxicity [72] .
Although it is still unknown whether these positive effects on myocytes biological properties are translatable to the human failing heart, a PDE5 activity in human heart has recently been documented, which seems to be involved in the cardiac contractile response to -adrenergic stimulation [38] . By virtue of findings obtained in animals demonstrating that cGMP catabolism by PDE5 regulates adrenergic cardiac contractility [39] , Borlaug et al. provided evidence that acute administration of 100 mg of sildenafil blunted the -receptor stimulated contractile response [38] . These results may have implications in HF patients with excessive sympathetic stimulation. Acute administration of sildenafil may also reduce cardiac norepinephrine spillover, an indicator of an inhibitory influence on the efferent sympathetic activity to the heart [137] . Considering that observations obtained in normal individuals suggest a pronounced increase of sympathetic nervous activity after 100 mg sildenafil [138] , more data are necessary in order to clarify the real impact of acute and chronic PDE5-inhibition on sympathetic nervous system activity in HF.
Effects on Pulmonary Hemodynamics and Function
HF patients present with increased pulmonary vascular resistance and secondary PH [139] . Lung dysfunction ensues due to endothelial dysfunction, loss of permeability to fluid and perfusion inequality. A ventilatory restrictive pattern [140] and impaired alveolar gas diffusion are the functional correlates [141] . Given the high selectivity of PDE5 for the lung microcirculation, hemodynamics and function have to be considered a primary target of PDE5-inhibitors.
Information regarding the effects of this class of drugs on pulmonary hemodynamics of HF patients suggests an activity similar to that reported for primary iPAH. In patients with left ventricular dysfunction and secondary PAH, 50 mg of sildenafil did not affect systemic blood pressure, lowered PVR and PAP and had no effect on PWCP. A variable influence on cardiac index has been reported according to the severity of the disease [142, 143] . Beneficial effects on pulmonary hemodynamics were detected also during exercise [143] .
In patients with stable moderate HF, 50 mg of sildenafil significantly improved lung diffusion capacity for carbon monoxide (DLCO) by 11%. This effect was determined by a specific increase in the alveolar-capillary membrane conductance (DM) properties without changes in the capillary blood volume (Vc). Interestingly, observed improvement was persistent even after normalization of DM for alveolar volume. These findings suggest that an increased NO availability is also important in the modulation of the tissue component of resistance to O 2 transfer from alveoli to hemoglobin [142] .
Oral sildenafil represents also a useful adjunctive therapy for treating PAH in patients undergoing left ventricular assist devices (LVADs) implantation. In fact, in a series of LVADs patients, there was additional reduction of PAP over iNO, and weaning from iNO and inotropes was facilitated without deleterious hemodynamic consequences [144] .
Effects on Systemic Vascular Tone and Endothelial Function
Abnormal systemic vascular tone and endothelial dysfunction are hallmarks of the HF syndrome, that contribute to heightened systemic vascular resistance (SVR). Hirata et al. [145] investigated the effects of 50 mg of sildenafil on peripheral resistance, large artery stiffness and wave reflection as major determinants of left ventricular afterload. They found an acute improvement in cardiac performance due to a combined decrease of all peripheral determinants. A similar effect on aortic pressure augmentation index has been reported in patients with hypertensive heart disease [60] , suggesting that by virtue of its effects on large systemic arteries, sildenafil could have a role also in the management of systemic hypertension. Remarkably, prolonged treatment (3 months) with sildenafil 50 mg 3 times/day modulated arterial wave reflection and decreased both systolic (-8 mmHg) and diastolic (-6 mmHg) ambulatory blood pressure [97] .
Endothelial function is severely impaired in HF. There are data to suggest that sildenafil may be of use in reversing endothelial dysfunction [61, 146] . Katz et al. studied the effect of PDE5-inhibition with three doses of sildenafil (12.5, 25 and 50 mg) on flow-mediated endothelium-dependent vasodilatation in the forearm circulation of 48 patients with stable HF, and found a dose dependent favorable effect starting with 25 mg. These data were confirmed by subsequent observations that even showed an additive effect on endothelial function of sildenafil 50 mg on top of the ACE-inhibitor ramipril 10 mg [147] .
The influence of PDE5-inhibitors on coronary hemodynamics in the setting of HF is poorly investigated. In an animal model of pacing-induced HF, sildenafil failed to show any effect on endothelium-dependent coronary vasodilation in response to acetylcholine. In addition, the compound did not alter the increase in coronary flow that occurred in response to the increased oxygen demand during exercise [148] .
Effects on Cardiopulmonary Exercise Performance
The improvement in maximal exercise capacity and O 2 uptake at peak exercise (VO 2 ) observed with PDE 5 inhibition may be attributable to several mechanisms 139, 140 . An important role is played by the pulmonary cGMP-mediated reduction in PAP and PVR and consequent improved pulmonary perfusion. The increased NO availability in lung capillaries may then improve their permeability and promote a more efficient gas exchange at the alveolar capillary level. An additional mechanism that may be at work in the augmented peak VO 2 is the increased cardiac index due to a reduction of conduit vessels afterload determinants [145] .
Despite sildenafil has not been shown to improve C(a-v)O2 and maximal O 2 extraction is preserved in HF patients, an improvement in aerobically regenerated ATP during exercise has been reported following PDE5-inhibition, based on an upward shift of the relationship VO 2 /work rate and a faster decay in VO 2 time constant during recovery phase after maximal exercise [142] . Related to this, a major role may be attributed to the improved vessel ability to accommodate incremental increases in blood flow and to a more proficient redistribution to working muscles [61, 146] .
An exaggerated ventilatory response (VE) to CO 2 output (VCO 2 ) occurs in HF patients and provides relevant prognostic information [149, 150] . Possible explanations for the inefficient ventilation may be an overactive chemoreflex and metaboreflex signaling to central controller of VE or an abnormal ventilation/perfusion (V/Q) matching.
Studies have consistently shown that sildenafil reduces the slope of VE/VCO 2 during exercise [142, 143] . An improvement in DLCO and a decrease of waste ventilation, as suggested by a reduction in dead space/tidal volume ratio, indicates an improved V/Q matching [142] . Furthermore, in a placebo-controlled trial aimed at investigating the long-term effects of sildenafil administration on exercise performance, it was found that a better perfusion to hypoxemic muscles reversed the metaboreflex activation and modulated the inefficient ventilatory response 3 .
